Your browser doesn't support javascript.
loading
Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial.
Bolhuis, Karen; Grosheide, Lodi; Wesdorp, Nina J; Komurcu, Aysun; Chapelle, Thiery; Dejong, Cornelis H C; Gerhards, Michael F; Grünhagen, Dirk J; van Gulik, Thomas M; Huiskens, Joost; De Jong, Koert P; Kazemier, Geert; Klaase, Joost M; Liem, Mike S L; Molenaar, I Quintus; Patijn, Gijs A; Rijken, Arjen M; Ruers, Theo M; Verhoef, Cornelis; de Wilt, Johannes H W; Punt, Cornelis J A; Swijnenburg, Rutger-Jan.
Afiliação
  • Bolhuis K; From the Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
  • Grosheide L; From the Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
  • Wesdorp NJ; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, The Netherlands.
  • Komurcu A; The Netherlands Netherlands Comprehensive Cancer Center, Utrecht, The Netherlands.
  • Chapelle T; Department of Hepatobiliary, Transplantation, and Endocrine Surgery, University of Antwerp, Belgium.
  • Dejong CHC; Maastricht University Medical Center, Department of Surgery, Maastricht, The Netherlands and Universitätsklinikum Aachen, Aachen, Germany.
  • Gerhards MF; Department of Surgery, OLVG Hospital, Amsterdam, The Netherlands.
  • Grünhagen DJ; Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, The Netherlands.
  • van Gulik TM; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
  • Huiskens J; SAS Institute B.V., Huizen, The Netherlands.
  • De Jong KP; Department of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen.
  • Kazemier G; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, The Netherlands.
  • Klaase JM; Department of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen.
  • Liem MSL; Department of Surgery, Medical Spectrum Twente, Enschede, the Netherlands.
  • Molenaar IQ; Regional Academic Cancer Center Utrecht, Department of Surgery, University Medical Center Utrecht and St Antonius Hospital Nieuwegein, The Netherlands.
  • Patijn GA; Department of Surgery, Isala, Zwolle, The Netherlands.
  • Rijken AM; Amphia hospital, Department of Surgery, Breda, The Netherlands.
  • Ruers TM; Amphia hospital, Department of Surgery, Breda, The Netherlands.
  • Verhoef C; Erasmus MC Cancer Institute, Department of Surgery, Rotterdam, The Netherlands.
  • de Wilt JHW; Radboud University Medical Center, Department of Surgery, Nijmegen, The Netherlands.
  • Punt CJA; From the Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
  • Swijnenburg RJ; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Department of Epidemiology, Utrecht, The Netherlands.
Ann Surg Open ; 2(3): e081, 2021 Sep.
Article em En | MEDLINE | ID: mdl-37635815
ABSTRACT

Objective:

To present short-term outcomes of liver surgery in patients with initially unresectable colorectal liver metastases (CRLM) downsized by chemotherapy plus targeted agents.

Background:

The increase of complex hepatic resections of CRLM, technical innovations pushing boundaries of respectability, and use of intensified induction systemic regimens warrant for safety data in a homogeneous multicenter prospective cohort.

Methods:

Patients with initially unresectable CRLM, who underwent complete resection after induction systemic regimens with doublet or triplet chemotherapy, both plus targeted therapy, were selected from the ongoing phase III CAIRO5 study (NCT02162563). Short-term outcomes and risk factors for severe postoperative morbidity (Clavien Dindo grade ≥ 3) were analyzed using logistic regression analysis.

Results:

A total of 173 patients underwent resection of CRLM after induction systemic therapy. The median number of metastases was 9 and 161 (93%) patients had bilobar disease. Thirty-six (20.8%) 2-stage resections and 88 (51%) major resections (>3 liver segments) were performed. Severe postoperative morbidity and 90-day mortality was 15.6% and 2.9%, respectively. After multivariable analysis, blood transfusion (odds ratio [OR] 2.9 [95% confidence interval (CI) 1.1-6.4], P = 0.03), major resection (OR 2.9 [95% CI 1.1-7.5], P = 0.03), and triplet chemotherapy (OR 2.6 [95% CI 1.1-7.5], P = 0.03) were independently correlated with severe postoperative complications. No association was found between number of cycles of systemic therapy and severe complications (r = -0.038, P = 0.31).

Conclusion:

In patients with initially unresectable CRLM undergoing modern induction systemic therapy and extensive liver surgery, severe postoperative morbidity and 90-day mortality were 15.6% and 2.7%, respectively. Triplet chemotherapy, blood transfusion, and major resections were associated with severe postoperative morbidity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Ann Surg Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Ann Surg Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda